Suven Life Sciences has received product patents from Israel, Macau and South Korea for New Chemical Entities (NCEs) used in the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2032, the Hyderabad-based company said in a statement.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Suven CEO Venkat Jasti said.
NCEs are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer, Attention deficient hyperactivity disorder, Huntington’s disease, Major Depressive disorder, Parkinsons and Schizophrenia.
Shares of Suven Life Sciences were trading 0.09 per cent lower at Rs 173 apiece on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.